The FDA approved 59 novel oncology therapeutics, sponsored by 25 different pharmaceutical companies, between 2012 and 2017. A study by Varma and colleagues reported in the British Medical Journal (BMJ) this month found that only one of these companies included a sufficient number of minority groups in their clinical trials. Just 56% of the sponsors adequately represented women in all clinical trials, and only 24% had a sufficient representation of older adults.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,